Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck Kgaa Spns/Adr (OP:MKKGY)

30.54 +0.71 (+2.38%)
Streaming Delayed Price Updated: 10:16 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck Kgaa Spns/Adr

< Previous 1 2 Next >
News headline image
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck ↗
Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA... 
Via Benzinga
News headline image
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors ↗
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT... 
Via Benzinga
News headline image
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share ↗
Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The... 
Via Benzinga
Topics Initial Public Offering
News headline image
MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript ↗
MKKGY earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer ↗
England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
Via Benzinga
News headline image
Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio ↗
Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.